Long-Term Tolerability and Safety Of Facilitated-Subcutaneous Infusion Of Human Immune Globulin G (IgG), 10%, and Recombinant Human Hyaluronidase (rHuPH20) (IGHy): A Phase 3 Extension Study In Patients With Primary Immunodeficiencies (PIs).

MLA

Melamed, Isaac Reuven, et al. “Long-Term Tolerability and Safety Of Facilitated-Subcutaneous Infusion Of Human Immune Globulin G (IgG), 10%, and Recombinant Human Hyaluronidase (RHuPH20) (IGHy): A Phase 3 Extension Study In Patients With Primary Immunodeficiencies (PIs).” Journal of Allergy & Clinical Immunology, vol. 133, no. s2, Feb. 2014, p. AB180. EBSCOhost, https://doi.org/10.1016/j.jaci.2013.12.645.

APA

Melamed, I. R., Wasserman, R. L., Stein, M., Rubinstein, A., Puck, J. M., Gupta, S., Engl, W., Leibl, H., Yel, L., & Schiff, R. I. (2014). Long-Term Tolerability and Safety Of Facilitated-Subcutaneous Infusion Of Human Immune Globulin G (IgG), 10%, and Recombinant Human Hyaluronidase (rHuPH20) (IGHy): A Phase 3 Extension Study In Patients With Primary Immunodeficiencies (PIs). Journal of Allergy & Clinical Immunology, 133(s2), AB180. https://doi.org/10.1016/j.jaci.2013.12.645

Chicago

Melamed, Isaac Reuven, Richard L. Wasserman, Mark Stein, Arye Rubinstein, Jennifer M. Puck, Sudhir Gupta, Werner Engl, Heinz Leibl, Leman Yel, and Richard I. Schiff. 2014. “Long-Term Tolerability and Safety Of Facilitated-Subcutaneous Infusion Of Human Immune Globulin G (IgG), 10%, and Recombinant Human Hyaluronidase (RHuPH20) (IGHy): A Phase 3 Extension Study In Patients With Primary Immunodeficiencies (PIs).” Journal of Allergy & Clinical Immunology 133 (s2): AB180. doi:10.1016/j.jaci.2013.12.645.